Long-term outcomes in lupus

Research output: Contribution to journalArticlepeer-review

Abstract

Systemic lupus erythematosus (SLE) can follow an unpredictable course and be either chronic or of a relapsing and remitting form. Current measures used to assess disease activity do little to help physicians predict disease flares or complications that may arise. There are serious musculoskeletal, renal, cardiovascular, and ocular effects associated with SLE and the majority of these adverse consequences are associated with the use of the corticosteroid prednisone in these patients. Pulsed-dose methylprednisone treatment during flares appears to carry less risk than increasing daily prednisone doses. However, medication that can lessen or eliminate steroid use in moderately affected patients is needed.

Original languageEnglish (US)
Pages (from-to)S480-S485
JournalAmerican Journal of Managed Care
Volume7
Issue number16 SUPPL. OCTOBER
StatePublished - Nov 20 2001
Externally publishedYes

ASJC Scopus subject areas

  • Health Policy

Fingerprint Dive into the research topics of 'Long-term outcomes in lupus'. Together they form a unique fingerprint.

Cite this